• Mario Silva, Nicola Sverzellati, Davide Colombi, Gianluca Milanese, Carlo La Vecchia, Carlotta Galeone, Alfonso Marchianò, and Ugo Pastorino.
• Department of Medicine and Surgery (DiMeC), Section of Radiology, Unit of Surgical Sciences, University of Parma, Padiglione Barbieri, Via Gramsci 14, 43126, Parma, Italy. mario.silva@unipr.it.
• BMC Pulm Med. 2017 Nov 25; 17 (1): 155.

BackgroundTo report the prevalence of pleural plaques in a lung cancer screening trial by low-dose computed tomography (LDCT) and to test the association with incidence of lung cancer and mortality.MethodsThe LDCT of 2303 screenees were retrospectively reviewed with the specific aim of describing the prevalence and features of pleural plaques. Self-administered questionnaire was used to assess asbestos exposure. Frequency of lung cancer, lung cancer mortality, and overall mortality were detailed according to presence of pleural findings. Statistical analyses included comparison of mean or median, contingency tables, and Cox model for calculation of hazard ratio (HR) and its 95% confidence interval (CI).ResultsAmong male screenees, 31/1570 (2%) showed pleural abnormalities, 128/1570 (8.2%) disclosed asbestos exposure, 23/31 (74.2%) subjects with pleural plaques consistently denied exposure to asbestos. There was a trend for higher frequency of lung cancer among subjects with pleural plaques (9.7% vs 4.2%). Lung cancer in subjects with pleural plaques was always diagnosed in advanced stage. Subjects with pleural plaques showed HR 5.48 (95% CI 1.61-18.70) for mortality from lung cancer.ConclusionsPleural plaques are a risk factor for lung cancer mortality that can be detected in lung cancer screening by LDCT, also in subjects that are not aware of asbestos exposure.Trial RegistrationNCT02837809 - Retrospectively registered July 1, 2016 - Enrolment of first participant September 2005.

23 keywords...

hide…